Notably, we found a significant reduction in the severity of microvesicular steatosis in HFD-fed mice following treatment with the PRR antagonist PRO20, which normalized the total steatosis area, reducing it to 10.6% ± 4.7% (p = 0.0007) (Figure 2D). This evidence concerns the gene ATP6AP2 and steatosis.